Fig. 4. Irreversible electroporation augments anti-CTLA-4 therapy and improves tumor outcome.
a Schematic of experimental design. Briefly, mice were injected intradermal (i.d.) with 1.0 × 106 TRAMP-C2 cells into the right flank, and animals were enrolled into the indicated treatment group when their tumor reached 4–5 mm in diameter. b Individual tumor growth curves following each treatment, with the time synchronized to treatment on day 0. c Averaged tumor growth curves from (b). d Individual tumor sizes on day 21 from each treatment group in (b). e Fraction of tumor-free mice from each group, at day 21 post-treatment. Data in (b–e) reflect n = 8–15 mice/group pooled from four independent experiments, with exact n shown on panel b Unpaired two-tailed Mann–Whitney test was performed; *p < 0.05; **p < 0.01. Bars represent mean ± S.E.M. Source data are provided as a Source Data File.